Genetic modification of cerebral arterial wall: implications for prevention and treatment of cerebral vasospasm.
Genetic modification of cerebral vessels represents a promising and novel approach for prevention and/or treatment of various cerebral vascular disorders, including cerebral vasospasm. In this review, we focus on the current understanding of the use of gene transfer to the cerebral arteries for prevention and/or treatment of cerebral vasospasm following subarachnoid hemorrhage (SAH). We also discuss the recent developments in vascular therapeutics, involving the autologous use of progenitor cells for repair of damaged vessels, as well as a cell-based gene delivery approach for the prevention and treatment of cerebral vasospasm.
Vijay
Anantha
A
Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Santhanam
R
R
Katusic
Zvonimir S
ZS
D000818:Animals; D002536:Cerebral Arteries / Q000378:metabolism* / Q000503:physiopathology; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis; D052250:Nitric Oxide Synthase Type III / Q000235:genetics; D018384:Oxidative Stress / Q000187:drug effects / Q000235:genetics; D012038:Regeneration / Q000187:drug effects / Q000235:genetics; D013234:Stem Cells / Q000166:cytology / Q000378:metabolism; D013345:Subarachnoid Hemorrhage / Q000150:complications*; D020301:Vasospasm, Intracranial / Q000235:genetics* / Q000517:prevention & control / Q000628:therapy*
D019332:Endothelin-1; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III